MARKET

ABEO

ABEO

Abeona Therapeut
NASDAQ
5.08
-0.28
-5.22%
After Hours: 5.09 +0.01 +0.20% 19:52 12/15 EST
OPEN
5.39
PREV CLOSE
5.36
HIGH
5.39
LOW
5.00
VOLUME
1.84M
TURNOVER
--
52 WEEK HIGH
7.54
52 WEEK LOW
3.933
MARKET CAP
275.29M
P/E (TTM)
4.595
1D
5D
1M
3M
1Y
5Y
1D
Abeona Therapeutics’ Strategic Advancements and Growing Demand Justify Buy Rating
TipRanks · 3d ago
ABEONA THERAPEUTICS® ANNOUNCES NEW QUALIFIED TREATMENT CENTER FOR ZEVASKYN® IN TEXAS
Reuters · 4d ago
Abeona Therapeutics: Promising Growth with ZEVASKYN’s Market Expansion and Strategic Advancements
TipRanks · 4d ago
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
Barchart · 5d ago
Abeona Therapeutics announces first patient treatment with ZEVASKYN
TipRanks · 12/08 12:35
Abeona Therapeutics Treats First Patient With FDA-Approved ZEVASKYN Gene Therapy
Reuters · 12/08 12:30
ABEONA THERAPEUTICS® ANNOUNCES FIRST PATIENT TREATMENT WITH ZEVASKYN® GENE THERAPY
Reuters · 12/08 12:30
Weekly Report: what happened at ABEO last week (1201-1205)?
Weekly Report · 12/08 09:21
More
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Webull offers Abeona Therapeutics Inc stock information, including NASDAQ: ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.